Valuation: Q-linea AB

Capitalization 143M 13.06M 12.36M 11.46M 10.25M 18.46M 1.11B 20.44M 52.7M 454M 49.06M 47.97M 1.96B P/E ratio 2024 *
-0.78x
P/E ratio 2025 * -1.82x
Enterprise value 115M 10.5M 9.94M 9.22M 8.24M 14.85M 890M 16.44M 42.39M 366M 39.46M 38.58M 1.57B EV / Sales 2024 *
2.36x
EV / Sales 2025 * 0.94x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+3.04%
1 week+3.39%
Current month+3.39%
1 month-36.13%
3 months-63.58%
6 months-51.87%
Current year-67.03%
More quotes
1 week
1.15
Extreme 1.15
1.40
1 month
0.90
Extreme 0.9
1.79
Current year
0.90
Extreme 0.9
5.60
1 year
0.90
Extreme 0.9
5.60
3 years
0.90
Extreme 0.9
120.80
5 years
0.90
Extreme 0.9
187.50
10 years
0.90
Extreme 0.9
187.50
More quotes
Director TitleAgeSince
Chief Executive Officer - 2024-02-29
Director of Finance/CFO 70 2023-04-30
Chief Operating Officer 55 2021-12-31
Manager TitleAgeSince
Chairman 55 2008-03-31
Chairman 62 2017-12-31
Director/Board Member 70 2017-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+3.04%+3.39%-50.41%-98.94%13.06M
+0.19%-2.43%-27.99%-63.08%14.12B
+1.60%-6.83%-42.70%-73.33%2.57B
+5.62%+6.94%-11.05% - 1.5B
+2.98%+2.19%-12.16%+223.70%1.41B
-0.74%+5.58%+29.89%-37.04%1.18B
+1.96%+3.34%-24.53%-60.66%889M
+0.96%-2.62%-25.86%+36.49%873M
-0.43%+1.10%+17.32%-50.76%773M
-1.87%-5.76%-18.89%-45.91%646M
Average +1.33%-0.78%-16.64%-18.84% 2.4B
Weighted average by Cap. +0.82%-2.01%-22.83%-39.99%
See all sector performances

Financials

2024 *2025 *
Net sales 48.55M 4.45M 4.21M 3.9M 3.49M 6.29M 377M 6.96M 17.95M 155M 16.71M 16.34M 667M 149M 13.64M 12.9M 11.96M 10.7M 19.28M 1.15B 21.34M 55.02M 474M 51.22M 50.08M 2.04B
Net income -218M -20M -18.92M -17.54M -15.69M -28.27M -1.69B -31.3M -80.7M -696M -75.13M -73.46M -3B -138M -12.68M -12M -11.12M -9.95M -17.92M -1.07B -19.84M -51.15M -441M -47.62M -46.56M -1.9B
Net Debt -27.88M -2.55M -2.42M -2.24M -2M -3.61M -216M -4M -10.31M -88.88M -9.6M -9.38M -383M -2.88M -264K -250K -231K -207K -373K -22.35M -413K -1.06M -9.18M -991K -969K -39.56M
More financial data * Estimated data
Logo Q-linea AB
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility profile within three to six hours directly from a positive blood culture, which enables early administration of antibiotics specifically targeting the disease-causing pathogen. Its main application is the identification of sepsis in hospital patients and the product is aimed primarily at hospital laboratories.
Employees
97
Calendar
More about the company
Date Price Change Volume
24-12-06 1.220 kr +3.04% 326,762
24-12-05 1.184 kr -0.67% 27,067
24-12-04 1.192 kr -1.00% 164,594
24-12-03 1.204 kr -2.43% 84,840
24-12-02 1.234 kr +4.58% 412,923

Delayed Quote Nasdaq Stockholm, December 06, 2024 at 12:00 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C
surperformance-ratings-light-chart Q-LINEA-ABMore Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. QLINEA Stock